Kadowaki, T., Tajima, N., Odawara, M., Minamide, T., Kawashima, M., Yanagida, D., Okamoto, T. and Arjona Ferreira, J.C. (2013) Efficacy and Safety of Sitagliptin Add-On Therapy in Japanese Patients with Type 2 Diabetes on Insulin Monotherapy. Diabetology International, 4, 160-172.
http://dx.doi.org/10.1007/s13340-013-0109-z

has been cited by the following article:

• TITLE: Sitagliptin for Elderly Patients Aged 75 Years or Older with Inadequately Controlled Type 2 Diabetes with Common Antidiabetes Treatments

  AUTHORS: Katsunori Suzuki, Yurie Mistuma, Takaaki Sato, Mariko Hatta

  KEYWORDS: Elderly, Sitagliptin, Type 2 Diabetes Mellitus

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.6 No.9, September 23, 2015

  ABSTRACT: Background: The purpose of this study was to evaluate the effects of sitagliptin in elderly patients with type 2 diabetes aged 75 years or older versus those aged 65 - 74 years. Methods: Outpatients aged 65 years or older with type 2 diabetes who received sitagliptin at a dose of 50 mg daily for 6 months were divided into two groups: those who were 75 years and older and those who were 65 - 74 years. The efficacy and safety were retrospectively evaluated by comparison of laboratory values before and after the administration of sitagliptin and by review of adverse events after treatment. Results: One hundred and twelve older patients with type 2 diabetes were studied. Six months after the initiation of sitagliptin, participants’ hemoglobin A1c was significantly decreased by 1.09% ± 0.8% in 65 - 74-year-olds (66 patients; mean age, 69.1 ± 3.0 years; mean HbA1c before administration, 8.4% ± 0.8%) and by 1.05% ± 0.8% in patients 75 years or older (46 patients; mean age, 79.8 ± 4.1 years; mean HbA1c before administration, 8.5% ± 0.7%). There was no significant difference in hemoglobin A1c between the two groups. Furthermore, sitagliptin was well tolerated in both age groups. Conclusions: In elderly patients (75 years or older) with type 2 diabetes, the effect of sitagliptin was similar that in older patients (younger than 75 years) with type 2 diabetes.